Tumorigenicity risk of iPSCs in vivo: nip it in the bud

In 2006, Takahashi and Yamanaka first created induced pluripotent stem cells from mouse fibroblasts via the retroviral introduction of genes encoding the transcription factors Oct3/4, Sox2, Klf44, and c-Myc. Since then, the future clinical application of somatic cell reprogramming technology has bec...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhong, Chaoliang, Liu, Miao, Pan, Xinghua, Zhu, Haiying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9026204/
https://www.ncbi.nlm.nih.gov/pubmed/35692443
http://dx.doi.org/10.1093/pcmedi/pbac004
_version_ 1784691067923202048
author Zhong, Chaoliang
Liu, Miao
Pan, Xinghua
Zhu, Haiying
author_facet Zhong, Chaoliang
Liu, Miao
Pan, Xinghua
Zhu, Haiying
author_sort Zhong, Chaoliang
collection PubMed
description In 2006, Takahashi and Yamanaka first created induced pluripotent stem cells from mouse fibroblasts via the retroviral introduction of genes encoding the transcription factors Oct3/4, Sox2, Klf44, and c-Myc. Since then, the future clinical application of somatic cell reprogramming technology has become an attractive research topic in the field of regenerative medicine. Of note, considerable interest has been placed in circumventing ethical issues linked to embryonic stem cell research. However, tumorigenicity, immunogenicity, and heterogeneity may hamper attempts to deploy this technology therapeutically. This review highlights the progress aimed at reducing induced pluripotent stem cells tumorigenicity risk and how to assess the safety of induced pluripotent stem cells cell therapy products.
format Online
Article
Text
id pubmed-9026204
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-90262042022-06-10 Tumorigenicity risk of iPSCs in vivo: nip it in the bud Zhong, Chaoliang Liu, Miao Pan, Xinghua Zhu, Haiying Precis Clin Med Review In 2006, Takahashi and Yamanaka first created induced pluripotent stem cells from mouse fibroblasts via the retroviral introduction of genes encoding the transcription factors Oct3/4, Sox2, Klf44, and c-Myc. Since then, the future clinical application of somatic cell reprogramming technology has become an attractive research topic in the field of regenerative medicine. Of note, considerable interest has been placed in circumventing ethical issues linked to embryonic stem cell research. However, tumorigenicity, immunogenicity, and heterogeneity may hamper attempts to deploy this technology therapeutically. This review highlights the progress aimed at reducing induced pluripotent stem cells tumorigenicity risk and how to assess the safety of induced pluripotent stem cells cell therapy products. Oxford University Press 2022-02-03 /pmc/articles/PMC9026204/ /pubmed/35692443 http://dx.doi.org/10.1093/pcmedi/pbac004 Text en © The Author(s) 2022. Published by Oxford University Press on behalf of the West China School of Medicine & West China Hospital of Sichuan University. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review
Zhong, Chaoliang
Liu, Miao
Pan, Xinghua
Zhu, Haiying
Tumorigenicity risk of iPSCs in vivo: nip it in the bud
title Tumorigenicity risk of iPSCs in vivo: nip it in the bud
title_full Tumorigenicity risk of iPSCs in vivo: nip it in the bud
title_fullStr Tumorigenicity risk of iPSCs in vivo: nip it in the bud
title_full_unstemmed Tumorigenicity risk of iPSCs in vivo: nip it in the bud
title_short Tumorigenicity risk of iPSCs in vivo: nip it in the bud
title_sort tumorigenicity risk of ipscs in vivo: nip it in the bud
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9026204/
https://www.ncbi.nlm.nih.gov/pubmed/35692443
http://dx.doi.org/10.1093/pcmedi/pbac004
work_keys_str_mv AT zhongchaoliang tumorigenicityriskofipscsinvivonipitinthebud
AT liumiao tumorigenicityriskofipscsinvivonipitinthebud
AT panxinghua tumorigenicityriskofipscsinvivonipitinthebud
AT zhuhaiying tumorigenicityriskofipscsinvivonipitinthebud

Ejemplares similares